Photocure ASA
Oslo Stock Exchange PHO.OL
Photocure ASA Net Income for the year ending December 31, 2023: USD 96.11 K
-
Photocure ASA Net Income for the year ending December 31, 2022 was USD -7.33 M, a -109.35% change year over year.
-
Photocure ASA Net Income for the year ending December 31, 2021 was USD -3.50 M, a -34.03% change year over year.
-
Photocure ASA Net Income for the year ending December 31, 2020 was USD -2.61 M, a -172.03% change year over year.
-
Photocure ASA Net Income for the year ending December 31, 2019 was USD 3.62 M, a 185.41% change year over year.
| Date | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) | Net Income Margin |
|---|
| CEO | Mr. Daniel Schneider |
| IPO Date | May 30, 2000 |
| Location | Norway |
| Headquarters | Hoffsveien 4 |
| Employees | 102 |
| Sector | Health Care |
| Industries | |
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email